Source comparison
Best Thymosin Alpha-1 Dosage for Infection Defense: Protocol Comparison
Acute Viral (Influenza, COVID-19) 1.6mg Twice weekly 10–14 days, then taper to 0.8mg if needed NK cell activation, dendritic cell maturation, IFN-gamma upregulation 40% reduction in progression to severe disease when started within 72 hours Chronic Viral (Hepa
This comparison does not assign a generated winner or score.
- Acute Viral (Influenza, COVID-19)
- 1.6mg
- Twice weekly
- 10–14 days, then taper to 0.8mg if needed
- NK cell activation, dendritic cell maturation, IFN-gamma upregulation
- 40% reduction in progression to severe disease when started within 72 hours
- Chronic Viral (Hepatitis B/C)
- 24–48 weeks
- CD4+ T-cell expansion, antigen-specific CTL response
- 36% HBeAg seroconversion vs 19% placebo in HBV trials
- Bacterial Sepsis
- 21–28 days
- Monocyte HLA-DR restoration, reversal of immune paralysis
- 22% reduction in 28-day mortality when added to standard care
- Opportunistic Infections (HIV, post-transplant)
- 0.8–1.6mg
- Ongoing until CD4+ >200 cells/µL
- Thymic T-cell output, restoration of T-cell diversity
- Median CD4+ increase of 210 cells/µL over 24 weeks
- Preventive (High Exposure Risk)
- 0.8mg
- Duration of exposure period
- Baseline NK cell priming, enhanced mucosal IgA
- Limited trial data. Primarily used in healthcare worker cohorts